2021
DOI: 10.3390/cells10082128
|View full text |Cite
|
Sign up to set email alerts
|

Occurrence and Antigenic Specificity of Perinuclear Anti-Neutrophil Cytoplasmic Antibodies (P-ANCA) in Systemic Autoimmune Diseases

Abstract: Perinuclear anti-neutrophilic cytoplasmic antibodies (P-ANCA) recognize heterogeneous antigens, including myeloperoxidase (MPO), lactoferrin, elastase, cathepsin-G and bactericidal/permeability-increasing protein. Although P-ANCA have diagnostic utility in vasculitides, they may also be found in patients with various other systemic autoimmune rheumatic diseases (SARDs). Nevertheless, the clinical significance and the targets recognized by P-ANCA in such patients remain unclear. For this purpose, herein we inve… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(2 citation statements)
references
References 34 publications
0
2
0
Order By: Relevance
“…Lactoferrin and cathepsin G are two additional antigens that have been shown to increase pANCA pattern. [34][35][36] Cathepsin G (CG) is an antimicrobial chymotrypsin-like enzyme that accounts for 18% of azurophil granule proteins. CG has been shown to act as a potent immune adjuvant by inducing the production of cytokines that promote T cell-dependent cellular immunity and antigen-specific Ig production.…”
Section: Discussionmentioning
confidence: 99%
“…Lactoferrin and cathepsin G are two additional antigens that have been shown to increase pANCA pattern. [34][35][36] Cathepsin G (CG) is an antimicrobial chymotrypsin-like enzyme that accounts for 18% of azurophil granule proteins. CG has been shown to act as a potent immune adjuvant by inducing the production of cytokines that promote T cell-dependent cellular immunity and antigen-specific Ig production.…”
Section: Discussionmentioning
confidence: 99%
“…As disease severity is an important determinant of patient outcomes in AAV, studies have attempted to explore novel biomarkers, with a special focus on assessing disease activity 4 , 5 . Traditionally, laboratory tests of myeloperoxidase (MPO) and proteinase 3 (PR3)-ANCAs are useful biomarkers for the diagnosis and assessment of prognosis in the context of MPA/GPA 6 , but also with limitations that its titres alone are not sufficient to confirm diagnosis or monitor therapeutic response during follow‐up of patients 7 . In the meanwhile, the Birmingham Vasculitis Activity Score (BVAS) 3.0, which is composed of 56 items with a maximum score of 63, is a clinical measure for objectively describing ongoing inflammation in AAV 8 .…”
Section: Introductionmentioning
confidence: 99%